Hailed several years ago as a breakthrough immunotherapy for prostate cancer, its Provenge vaccine seemed likely to win FDA approval five years ago until an unusual turn of events prompted the agency to issue a delay.

FORBES: A Dendreon Post Mortem? Maybe Not Yet, But...